Blue Fin Capital Inc. Sells 162 Shares of Illumina, Inc. (NASDAQ:ILMN)

Blue Fin Capital Inc. lessened its holdings in Illumina, Inc. (NASDAQ:ILMNGet Rating) by 8.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,831 shares of the life sciences company’s stock after selling 162 shares during the period. Blue Fin Capital Inc.’s holdings in Illumina were worth $349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in ILMN. Private Trust Co. NA acquired a new stake in shares of Illumina in the 2nd quarter valued at $25,000. Glassman Wealth Services lifted its position in Illumina by 72.9% during the 2nd quarter. Glassman Wealth Services now owns 147 shares of the life sciences company’s stock worth $27,000 after buying an additional 62 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its position in Illumina by 50.0% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 183 shares of the life sciences company’s stock worth $35,000 after buying an additional 61 shares in the last quarter. WASHINGTON TRUST Co lifted its position in Illumina by 100.0% during the 2nd quarter. WASHINGTON TRUST Co now owns 200 shares of the life sciences company’s stock worth $37,000 after buying an additional 100 shares in the last quarter. Finally, WFA of San Diego LLC acquired a new position in Illumina during the 2nd quarter worth about $37,000. Institutional investors and hedge funds own 87.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Bank of America reduced their price target on shares of Illumina from $220.00 to $210.00 in a research report on Tuesday, January 10th. Citigroup downgraded shares of Illumina from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $200.00 to $180.00 in a research report on Monday, December 12th. StockNews.com initiated coverage on shares of Illumina in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. Canaccord Genuity Group cut their target price on shares of Illumina from $340.00 to $330.00 and set a “buy” rating on the stock in a research report on Friday, November 4th. Finally, Credit Suisse Group cut their target price on shares of Illumina from $230.00 to $225.00 and set a “neutral” rating on the stock in a research report on Friday, November 4th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $252.84.

Insider Buying and Selling

In related news, SVP Aimee L. Hoyt sold 871 shares of the stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $205.57, for a total transaction of $179,051.47. Following the completion of the sale, the senior vice president now directly owns 2,796 shares of the company’s stock, valued at approximately $574,773.72. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, SVP Susan H. Tousi sold 500 shares of the firm’s stock in a transaction that occurred on Friday, January 6th. The shares were sold at an average price of $204.58, for a total transaction of $102,290.00. Following the completion of the transaction, the senior vice president now directly owns 38,662 shares of the company’s stock, valued at approximately $7,909,471.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Aimee L. Hoyt sold 871 shares of the firm’s stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $205.57, for a total transaction of $179,051.47. Following the transaction, the senior vice president now directly owns 2,796 shares of the company’s stock, valued at $574,773.72. The disclosure for this sale can be found here. In the last three months, insiders sold 2,371 shares of company stock valued at $499,481. 0.13% of the stock is owned by corporate insiders.

Illumina Stock Performance

Shares of ILMN stock opened at $204.39 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.93 and a quick ratio of 0.72. The stock has a market cap of $32.15 billion, a PE ratio of -7.74 and a beta of 1.14. The stock has a 50-day moving average of $207.79 and a 200-day moving average of $207.68. Illumina, Inc. has a one year low of $173.45 and a one year high of $383.98.

Illumina (NASDAQ:ILMNGet Rating) last posted its earnings results on Thursday, November 3rd. The life sciences company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.05. Illumina had a positive return on equity of 4.36% and a negative net margin of 88.40%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.10 billion. As a group, sell-side analysts expect that Illumina, Inc. will post 2.23 earnings per share for the current year.

Illumina Company Profile

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Featured Articles

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNGet Rating).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.